Skip to main content

Table 4 Bivariate regression analysis and associated factors of DNOS of persons with dementia

From: Prevalence of dementia diagnoses not otherwise specified in eight European countries: a cross-sectional cohort study

 

Dementia diagnosis when living at home

Dementia diagnosis when living in a nursing home

DNOS

n = 193

Othera

n = 1021

OR

CI 95%

p value

DNOS

n = 170

Othera

n = 620

OR

CI 95%

p value

Person with dementia

 Age, years, median (Q1; Q3)

84 (80; 88)

82 (78; 86)

1.048

1.023–1.074

< 0.001

85 (80; 90)

84 (80; 88)

1.026

0.999–1.055

0.061

 Gender, female %

66

63

1.163

0.840–1.608

0.363

75

74

1.053

0.714–1.555

0.793

 Symptoms, years (range)

4 (2; 6)

4 (2; 6)

0.978

0.931–1.028

0.381

3 (1; 5)

4 (2; 7)

0.907

0.849–0.969

0.004

Comorbidity (CCI), median (Q1; Q3), 0–37

2 (1; 3)

2 (1; 3)

–

–

0.050

2 (1; 3)

2 (1; 3)

–

–

0.994

Cognitive function (SMMSE), 0–30

15 (10; 19)

15 (10; 20)

0.987

0.963–1.011

0.284

13 (8; 17)

12 (7; 16)

1.023

0.992–1.055

0.154

Quality of life (QoL-AD), 13–52

34 (30; 38)

34 (30; 38)

0.996

0.965–1.027

0.789

33 (29; 36)

33 (28; 37)

0.996

0.962–1.030

0.802

Activities of daily living (Katz ADL), 0–6

3 (1; 5)

3 (2; 5)

–

–

0.098

2 (1; 3)

2 (1; 4)

–

–

0.397

Depression in dementia (CSDD), 0–38

8 (5; 13)

7(3; 12)

1.032

1.006–1.059

0.016

5 (2; 9)

2 (2; 9)

0.991

0.956–1.027

0.611

Resource utilization (RUD) last 30 days, %

 Hospital admission, geriatric ward

1 (1)

42 (2)

0.121

0.017–0.887

0.038

0 (0)

1 (1)

0.000

0.000

1.000

 Visit general practitioner

95 (48)

403 (40)

1.487

1.092–2.024

0.012

73 (43)

93 (47)

0.840

0.597–1.183

0.840

 Visit geriatrician

5 (3)

75 (7)

0.335

0.134–0.841

0.020

17 (10)

55 (9)

1.139

0.643–2.020

0.655

 Visit neurologist

14 (7)

44 (4)

1.737

0.932–3.235

0.082

30 (18)

43 (7)

2.875

1.741–4.748

< 0.001

 Visit psychiatrist

2 (1)

2 (4)

0.435

0.102–1.856

0.261

8 (5)

27 (4)

1.083

0.483–2.429

0.847

Neuropsychiatric symptoms (NPI-Q)

 Severity, 0–36

10 (6; 15)

8 (5; 14)

1.028

1.004–1.052

0.021

5 (2; 9)

6 (3; 11)

0.969

0.939–0.999

0.043

Psychotropics, n (%)

112 (58)

814 (80)

0.352

0.254–0.486

< 0.001

122 (72)

513 (83)

0.702

0.493–0.998

0.049

 Antipsychotics

56 (29)

241 (24)

1.323

0.939–1.864

0.110

68 (40)

228 (37)

1.146

0.810–1.623

0.442

 Anxiolytic

19 (10)

173 (17)

0.535

0.324–0.883

0.014

25 (15)

190 (31)

0.390

0.247–0.617

< 0.001

 Sedatives

14 (7)

136 (13)

0.509

0.287–0.903

0.021

24 (14)

143 (23)

0.548

0.343–0.878

0.012

 Antidepressants

29 (15)

330 (32)

0.370

0.244–0.561

< 0.001

44 (26)

175 (28)

0.888

0.604–1.305

0.546

 Anti-dementia medication

43 (22)

585 (57)

0.214

0.149–0.307

< 0.001

37 (22)

271 (44)

0.358

0.241–0.533

< 0.001

  1. Italicized values indicates a positive result, e.g., 0–36
  2. p ≤ 0.05 was regarded as significant; significant p-values are marked in bold
  3. AD Alzheimer’s disease, CCI Charlson comorbidity index, CI Confidence interval, CSDD Cornell scale for depression in dementia, FTD Frontotemporal dementia, Katz-ADL Katz index of independence in activities of daily living, LBD Lewy body dementia, n Number of participants, NL The Netherlands, NPI-Q Neuropsychiatric inventory questionnaire, OR Odds ratio, Q1 First quartile, Q3 Third quartile, QoL-AD Quality of life in AD, RUD Resource utilization in dementia questionnaire, SD Standard deviation, SMMSE Standardized mini-mental state, UK United Kingdom, VaD Vascular dementia
  4. aAD, AD/VaD/FTD/LBD/other
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us